Advertisement

Advertisement

BSEM Stock Latest News

BioStem Technologies announces notice of allowance for four patents

The FlyBioStem Technologies announces notice of allowance for four patents

BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright

PremiumThe Fly

BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright

9d ago

BioStem Technologies (BSEM) Q1 Earnings Cheat Sheet

PremiumPre-Earnings

BioStem Technologies (BSEM) Q1 Earnings Cheat Sheet

12d ago

Biostem Technologies initiated with a Buy at H.C. Wainwright

PremiumThe Fly

Biostem Technologies initiated with a Buy at H.C. Wainwright

17d ago

BioStem Technologies Balances Bold Acquisition With Strain

PremiumCompany Announcements

BioStem Technologies Balances Bold Acquisition With Strain

2M ago

BSEM Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-EarningsBSEM Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

BioStem’s Diabetic Foot Ulcer Trial Reaches Completion: What Investors Should Watch Next

Company Announcements

BioStem’s Diabetic Foot Ulcer Trial Reaches Completion: What Investors Should Watch Next

4M ago

BioStem Technologies Q3 Earnings Call Highlights Resilience

Company Announcements

BioStem Technologies Q3 Earnings Call Highlights Resilience

6M ago

BioStem Technologies Reports Q3 2025 Financial Results

PremiumCompany Announcements

BioStem Technologies Reports Q3 2025 Financial Results

6M ago

BSEM Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

BSEM Upcoming Earnings Report: What to Expect?

6M ago

BioStem Technologies’ Promising Clinical Trial for Venous Leg Ulcers: A Potential Game-Changer

PremiumCompany Announcements

BioStem Technologies’ Promising Clinical Trial for Venous Leg Ulcers: A Potential Game-Changer

7M ago

BioStem Technologies’ Promising Study on Diabetic Foot Ulcers: A Potential Game-Changer

PremiumCompany Announcements

BioStem Technologies’ Promising Study on Diabetic Foot Ulcers: A Potential Game-Changer

7M ago

BioStem Technologies’ Earnings Call: Mixed Sentiment Amid Growth Plans

PremiumCompany AnnouncementsBioStem Technologies’ Earnings Call: Mixed Sentiment Amid Growth Plans

9M ago

BioStem Technologies Reports Q2 2025 Financial Results

Company Announcements

BioStem Technologies Reports Q2 2025 Financial Results

9M ago

BioStem Technologies’ Innovative Approach to Healing Venous Leg Ulcers: A Clinical Study Update

Company Announcements

BioStem Technologies’ Innovative Approach to Healing Venous Leg Ulcers: A Clinical Study Update

10M ago

BioStem’s BR-AM Trial: A Potential Game-Changer for Diabetic Foot Ulcers

PremiumCompany Announcements

BioStem’s BR-AM Trial: A Potential Game-Changer for Diabetic Foot Ulcers

10M ago

BioStem Technologies Advances Diabetic Foot Ulcer Treatment with BR-AM Study

PremiumCompany Announcements

BioStem Technologies Advances Diabetic Foot Ulcer Treatment with BR-AM Study

10M ago

BioStem Technologies’ Promising Study on Venous Leg Ulcer Treatment

PremiumCompany Announcements

BioStem Technologies’ Promising Study on Venous Leg Ulcer Treatment

11M ago

BioStem Technologies’ Promising Clinical Study on Venous Leg Ulcers

PremiumCompany Announcements

BioStem Technologies’ Promising Clinical Study on Venous Leg Ulcers

11M ago

BioStem Technologies’ Promising Clinical Study on Venous Leg Ulcers

PremiumCompany AnnouncementsBioStem Technologies’ Promising Clinical Study on Venous Leg Ulcers

11M ago

BioStem’s Innovative Approach to Diabetic Foot Ulcers: A Clinical Study Update

Company Announcements

BioStem’s Innovative Approach to Diabetic Foot Ulcers: A Clinical Study Update

11M ago

BioStem Technologies’ Promising Study on Venous Leg Ulcer Treatment

Company Announcements

BioStem Technologies’ Promising Study on Venous Leg Ulcer Treatment

11M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >